Clinical Trial

The Metformin Active Surveillance Trial (MAST) Study

Study Description

The Metformin Active Surveillance Trial (MAST) Study

This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Metformin

One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.

Drug - Placebo

One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.

Additional Information

Official Study Title

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study

Clinical Trial ID

NCT01864096

ParticipAid ID

1aKLrb